eXoZymes, Inc. (NASDAQ: EXOZ) is a biotechnology company specializing in the discovery and development of exosome‐based enzyme therapeutics. The company’s core mission revolves around harnessing the natural capabilities of cellular exosomes—small, lipid‐bound vesicles—to deliver targeted enzyme treatments for digestive disorders and metabolic diseases. By integrating state-of-the-art isolation techniques with proprietary formulation approaches, eXoZymes seeks to improve bioavailability and specificity of enzyme therapies, offering potential alternatives to traditional oral and injectable treatments.
Since its founding in 2015, eXoZymes has built a robust technology platform that underlies its lead product candidates. The company’s ExoDeliver™ system uses optimized surface engineering to direct enzymes precisely to affected tissues, minimizing systemic exposure and reducing off-target effects. Its pipeline includes a pancreatic enzyme replacement candidate targeting exocrine pancreatic insufficiency, as well as novel enzyme constructs designed to modulate gut microbiota in inflammatory bowel conditions. Preclinical studies have demonstrated favorable stability and activity profiles, paving the way for planned clinical trials in key therapeutic areas.
Headquartered in Cambridge, Massachusetts, eXoZymes maintains research collaborations and pilot manufacturing sites across North America and Europe. The company has entered strategic partnerships with academic institutions and contract development organizations to accelerate process development and scale-up. These alliances support both enzyme discovery and GMP manufacturing, ensuring streamlined progression from laboratory to clinical grade material. eXoZymes also pursues global regulatory engagement to facilitate multi-region development plans.
Under the leadership of CEO and co-founder Dr. Alicia Moreno, a veteran in exosome biology and enzyme engineering, eXoZymes is guided by an executive team with deep expertise in biopharmaceutical R&D and commercialization. The board includes industry luminaries in orphan drug development and digestive health. Drawing on a strong scientific foundation and clear strategic vision, eXoZymes aims to transform enzyme therapy through advanced exosome technologies, addressing unmet needs in gastrointestinal and metabolic medicine.
AI Generated. May Contain Errors.
